Weight Loss Injections and Thyroid Issues: What You Need to Know Before Starting

Medullary thyroid carcinoma (MTC) and MEN2 are contraindications for both tirzepatide (Mounjaro) and semaglutide (Wegovy) — personal or family history of either requires disclosure at consultation.
Most people with common thyroid conditions such as treated hypothyroidism or Hashimoto's thyroiditis are not automatically excluded, but clinical review is required to assess individual suitability.
GLP-1 medicines slow gastric emptying, which may affect the absorption timing of levothyroxine, thyroid hormone levels should be monitored once treatment begins.
Animal studies have shown thyroid C-cell changes at high GLP-1 receptor agonist doses; no equivalent effect has been confirmed in humans, but the product information carries a precautionary note.

If you have a thyroid condition and are considering weight loss injections, the short answer is: suitability depends on your specific diagnosis, current thyroid function, and medication — a prescriber needs to review your case individually. GLP-1 medicines such as Mounjaro and Wegovy are not blanket-excluded for people with thyroid disease, but certain thyroid conditions, particularly a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2), are listed contraindications in both medicines' licensed product information. These are prescription-only medicines; a clinician assesses your full health picture before any prescription is issued.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence, the prescribing rules, and practical monitoring actually mean for you

You've been told to look into your options, but your thyroid history complicates things

That's a position a lot of people find themselves in. Your GP has suggested losing weight to ease another condition, or you've read about GLP-1 medicines and wondered whether your thyroid diagnosis closes that door. The honest picture is more nuanced than a simple yes or no.

For the most common thyroid conditions (autoimmune hypothyroidism (Hashimoto's), treated underactive thyroid on stable levothyroxine, or a managed overactive thyroid) there is no blanket contraindication in the licensed product information for tirzepatide or semaglutide. The NHS patient information for tirzepatide does not list well-controlled hypothyroidism as a reason to avoid the medicine. What it does list clearly is a personal or family history of medullary thyroid carcinoma or MEN2. If either of those applies to you, these medicines are not suitable, full stop.

Beyond those specific contraindications, the conversation shifts to monitoring rather than exclusion. A prescriber reviewing your case will want to know your current thyroid-stimulating hormone (TSH) reading, which medication you take and at what dose, and how stable your thyroid function has been. A quick check (pull up your most recent blood test result on the NHS app before your consultation) takes under a minute and gives the prescriber exactly what they need. We cover the cancer-history angle, alongside how weight loss injections relate to thyroid conditions more broadly, if that's the specific concern you have. We also cover the cancer-history angle in more detail on its own dedicated page if that's the specific concern you have.

The levothyroxine timing question, and why it actually matters here

One practical issue that tends to get underplayed in general GLP-1 information is the interaction between these medicines and levothyroxine absorption. Levothyroxine is extremely sensitive to what's in your gut at the time you take it, it should already be taken on an empty stomach for that reason. GLP-1 receptor agonists slow gastric emptying as part of how they work; this has the potential to alter how consistently levothyroxine is absorbed, which could shift your TSH over time even if your dose hasn't changed.

No clinical guideline currently mandates a specific change to how you take levothyroxine when starting a GLP-1 medicine, but standard prescribing advice is to flag this to the clinician managing your thyroid condition so they can arrange thyroid function monitoring in the months after you start. The NHS England guidance on weight management injections advises telling all your healthcare providers about any new medicine you're starting, that includes your GP and endocrinologist if you have one.

For patients using oral contraceptives alongside tirzepatide, the absorption point becomes even more relevant; the prescribing rules around that are worth discussing at consultation too. If you're on HRT, NHS England specifically suggests considering transdermal options while on tirzepatide, for similar reasons. These are conversations to have openly, not afterthoughts.

What the animal-study data means for real-world risk, and what's still uncertain

Rodent studies during drug development showed C-cell hyperplasia and thyroid tumours at GLP-1 receptor agonist exposures far exceeding human therapeutic doses. It's a finding that's noted in the SmPCs for both tirzepatide and semaglutide as a precaution. The important context, highlighted in the NICE appraisal of tirzepatide (TA1026), is that rodent C-cells express GLP-1 receptors at a density humans' do not, and long-term pharmacovigilance data in humans has not confirmed a causal link to thyroid cancer. The MHRA continues to monitor this through post-marketing surveillance; both medicines carry a Black Triangle (▼) designation, meaning they are subject to additional reporting.

What remains genuinely uncertain is whether very long-term use at high doses carries any small residual risk in humans. Given that uncertainty, both medicines' product information asks prescribers to use clinical judgement in patients with any pre-existing thyroid pathology, and to take a history of thyroid cancer seriously as an exclusion. If you've had thyroid surgery, radioiodine treatment, or a previous thyroid cancer diagnosis, be specific about the type during your consultation, papillary or follicular thyroid cancer does not carry the same contraindication as medullary, but full disclosure is essential for a safe clinical decision. Our page on weight loss injections for thyroid patients goes through the distinctions by thyroid condition type if you want to read further before consulting.

How suitability gets decided, and what a prescriber needs from you

A prescriber reviewing a case like yours is working through a checklist that covers your thyroid diagnosis and its current status, your medication list (levothyroxine dose, any carbimazole, recent blood results), family cancer history, BMI, and any other weight-related conditions. They are not looking for reasons to say no, they are looking for the full picture so they can say yes safely, or flag something that needs a specialist's sign-off first. It's also worth knowing that prescribers will consider related factors, such as how weight loss injections can affect the gallbladder, and the vision changes that some people using weight loss injections have reported, so that your full medical picture is accounted for.

At nume, a real clinician reads your consultation the same day, not automated software, not a scoring algorithm, but a GPhC-registered Independent Prescriber who can ask follow-up questions if something needs clarifying. If your thyroid situation needs input from your GP or endocrinologist before a prescription can be issued, they'll tell you that clearly. You can find out more about how our clinical team works on our clinical team page, or get a broader sense of what weight loss treatments involve on our treatments overview. For any questions before you start, our team is reachable via the contact page.

If you're ready to take that step, a free consultation is the right place to begin. Speak to our prescribers about whether a weight loss injection is suitable for your specific thyroid history.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions